Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed)

The Core Centers for Clinical Research (CCCR) program is a forecasted federal funding opportunity expected to be released by the National Institutes of Health, specifically through the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This initiative reflects the agency’s long-standing mission to support research that improves the understanding, prevention, diagnosis, and treatment of arthritis, musculoskeletal, rheumatic, and skin diseases. As part of the U.S. Department of Health and Human Services, NIH funding programs are designed to advance scientific discovery and improve public health outcomes nationwide, and this opportunity continues that mandate by emphasizing clinical research infrastructure and methodological innovation. The primary purpose of the CCCR program is to support centralized research hubs that advance methodological sciences in clinical research. These centers are expected to focus on improving how clinical studies are designed, conducted, and evaluated in areas relevant to NIAMS priorities. Rather than funding direct biological or genetic discovery, the program emphasizes the development of new methods, metrics, and outcome measures that address gaps in clinical research. A key requirement is the inclusion of a strong Methodologic Core that drives innovation in study design and evaluation, along with a modest Administrative Core to support operations. Applicants may also include additional Resource Cores if justified by the research objectives. Funding under this opportunity is expected to support collaborative, interdisciplinary efforts that integrate expertise across multiple domains. The program encourages applicants to build partnerships among investigators with complementary skills, particularly those combining clinical, methodological, and patient-centered research expertise. A distinctive feature of the CCCR program is its requirement to incorporate patient and community perspectives throughout the research lifecycle. This includes ensuring representation in study design, implementation, and dissemination, thereby aligning research outcomes with real-world needs and priorities. Eligible applicants span a wide range of organizational types, including state and local governments, tribal governments and organizations, nonprofit entities, for-profit organizations, small businesses, and institutions of higher education. Both public and private academic institutions are eligible, as well as independent school districts and housing authorities. This broad eligibility framework reflects NIH’s commitment to inclusivity and the recognition that impactful clinical research can emerge from diverse institutional settings. The application process is expected to follow standard NIH submission procedures through Grants.gov and associated federal systems. While specific application components are not detailed in the forecast, NIH grants of this type typically require comprehensive research plans, descriptions of core structures, collaboration strategies, and justification of methodological innovation. Applicants are encouraged to begin preparing early, particularly by forming partnerships and defining research priorities that align with NIAMS objectives. No cost sharing or matching requirement is specified for this program. The timeline for this opportunity indicates that it is currently in a forecast stage, with an estimated posting date of May 25, 2026, and an anticipated application deadline of September 25, 2026. Awards are expected to be issued around July 1, 2027, with project start dates aligned to that timeline. This extended lead time allows applicants to develop robust proposals and collaborative frameworks. As a forecasted opportunity, the program provides advance notice rather than a finalized solicitation, signaling NIH’s intent to release a formal Notice of Funding Opportunity in the near future. Contact information for this program is provided through a designated NIH program officer, who can offer guidance and clarification during the pre-release phase. Prospective applicants are encouraged to engage with the contact to better understand program priorities and expectations. Overall, the CCCR program represents a strategic investment in improving the methodological foundations of clinical research, with the ultimate goal of enhancing outcomes in musculoskeletal, rheumatic, and skin disease care.

Focus on building interdisciplinary collaborations and demonstrating strong methodological innovation aligned with NIAMS priorities; ensure inclusion of patient and community perspectives throughout research design and implementation